Extrait

• For Group A (persitient macular edema): To investigate the change in macular edema measured with standard optical coherence tomography (OCT) and the absolute change in visual acuity following intravitreal administered injections of Bevacizumab (Avastin®) compared with intravitreal administered injections of Ranibizumab (Lucentis®) in patients with persistent diabetic macular edema following grid lasercoagulation. • For Group B (persistent neovascularisation): To investigate the change of neovascularisation and vitreous hemorrhage following intravitreal administered injections of Bevacizumab (Avastin®) compared with intravitreal administered injections of Ranibizumab (Lucentis®) as assessed by fundus photography and fluorescence angiography and the absolute change in visual acuity.

Critère d'inclusion

• persistent diabetic macula edema or persistent diabetic proliferative retinopathy after lasercoagulation

Liens

• euctr
• ictrp